Related Experiment Videos
Pulmonary involvement in polymyositis and in dermatomyositis
I Marie1, P Y Hatron, E Hachulla
1Département de Médecine Interne, Hôpital Claude Huriez, CHU Lille, France.
The Journal of Rheumatology
|July 24, 1998
Summary
Pulmonary involvement affects 40% of polymyositis (PM) and dermatomyositis (DM) patients, often leading to severe lung disease. High serum GOT, ferritin, anti-Jo-1 antibodies, and microangiopathy may predict this complication.
Area of Science:
- Rheumatology
- Pulmonology
- Internal Medicine
Background:
- Polymyositis (PM) and dermatomyositis (DM) are inflammatory myopathies.
- Pulmonary involvement is a significant complication in PM and DM.
Purpose of the Study:
- To determine the prevalence and characteristics of lung involvement in PM and DM patients.
- To identify predictive factors for pulmonary complications in PM and DM.
Main Methods:
- Retrospective review of 55 PM and DM patients diagnosed between 1983 and 1996.
- Diagnosis based on Bohan and Peter criteria.
Main Results:
- 40% of patients developed lung impairment, with interstitial lung disease, ventilatory insufficiency, and alveolitis as primary manifestations.
- Pulmonary involvement was associated with high morbidity (40%) and mortality (27%).
- Predictive factors included elevated serum GOT and ferritin, anti-Jo-1 antibody, and microangiopathy.
Conclusions:
- Pulmonary involvement is prevalent and severe in PM and DM patients.
- Elevated serum GOT and ferritin, anti-Jo-1 antibody, and microangiopathy are potential predictors of lung disease.
- Early detection of pulmonary dysfunction is crucial in PM and DM management.